CD274 and cancer: A phase II clinical trial (AstraZeneca, NCT02583477), for example, investigated the benefit of Durvalumab, a monoclonal antibody that blocks programmed cell death ligand-1 (PDL-1), combined with additional cancer drugs for metastatic PDAC.